PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions

Brainstorm Cell Therapeutics Inc. (BCLI)

Equity · Currency in USD · Last updated Dec 9, 2023
SummaryFinancials

Company Info

ISINUS10501E2019
CUSIP10501E201
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$9.81M
EPS-$0.42
EBITDA (TTM)-$21.28M
Year Range$0.13 - $3.46
Target Price$5.25
Short %8.09%
Short Ratio3.10

Share Price Chart


Loading data...

Performance

The chart shows the growth of an initial investment of $10,000 in Brainstorm Cell Therapeutics Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


0.00%200.00%400.00%600.00%800.00%JulyAugustSeptemberOctoberNovemberDecember
-40.65%
427.02%
BCLI (Brainstorm Cell Therapeutics Inc.)
Benchmark (^GSPC)

S&P 500

Compare to other instruments

Search for stocks, ETFs, and funds to compare with BCLI

Brainstorm Cell Therapeutics Inc.

Return

Brainstorm Cell Therapeutics Inc. had a return of -87.79% year-to-date (YTD) and -86.19% in the last 12 months. Over the past 10 years, Brainstorm Cell Therapeutics Inc. had an annualized return of -21.57%, while the S&P 500 had an annualized return of 9.85%, indicating that Brainstorm Cell Therapeutics Inc. did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date-87.79%19.92%
1 month16.32%5.06%
6 months-92.92%7.11%
1 year-86.19%16.17%
5 years (annualized)-42.06%11.84%
10 years (annualized)-21.57%9.85%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2023-1.38%-27.72%-10.68%-7.07%-88.30%-23.54%82.35%

Risk-Adjusted Performance

This table presents a comparison of risk-adjusted performance metrics for Brainstorm Cell Therapeutics Inc. (BCLI) and S&P 500 (^GSPC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
BCLI
Brainstorm Cell Therapeutics Inc.
-0.58
^GSPC
S&P 500
1.25

Sharpe Ratio

The current Brainstorm Cell Therapeutics Inc. Sharpe ratio is -0.58. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-0.500.000.501.00JulyAugustSeptemberOctoberNovemberDecember
-0.58
1.25
BCLI (Brainstorm Cell Therapeutics Inc.)
Benchmark (^GSPC)

Dividend History


Brainstorm Cell Therapeutics Inc. doesn't pay dividends

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%JulyAugustSeptemberOctoberNovemberDecember
-99.61%
-4.01%
BCLI (Brainstorm Cell Therapeutics Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Brainstorm Cell Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Brainstorm Cell Therapeutics Inc. was 99.71%, occurring on Nov 2, 2023. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.71%Jan 10, 20054658Nov 2, 2023
-50%Nov 11, 200317May 21, 200446Nov 4, 200463
-13.33%Jun 20, 20031Jun 20, 20031Jul 31, 20032
-9.53%Jun 12, 20031Jun 12, 20031Jun 19, 20032
-9%Jan 4, 20052Jan 5, 20051Jan 6, 20053

Volatility Chart

The current Brainstorm Cell Therapeutics Inc. volatility is 74.14%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%20.00%40.00%60.00%80.00%100.00%JulyAugustSeptemberOctoberNovemberDecember
74.14%
2.77%
BCLI (Brainstorm Cell Therapeutics Inc.)
Benchmark (^GSPC)